Don Creighton has more than 20 of years of experience in industry, consulting and scientific research with expert knowledge of payer systems and pricing & market access strategy.
Don has worked across a broad array of therapy areas and geographies with projects spanning the development continuum including US and global pricing and contracting strategies for Phase III / launch, Phase II assessments to inform Phase III ’go/no go’ and protocol development as well as early phase and BD/in-licensing evaluations for pipeline prioritization and asset acquisition decisions.
Prior to joining Huron, Don worked in the Commercialization & Outcomes Division of ICON Clinical Research for six years, leading the Global Pricing & Market Access Practice since 2016. He also serves on the In Vivo Advisory Editorial Board.
Previously, Don worked at Pfizer for nine years serving as Global Market Access Lead in the Specialty Care and Oncology Business Units, where he launched the first NSCLC therapy with a companion diagnostic, XALKORI. He started his career at Cambridge Pharma Consultancy (now part of IQVIA/ IMS Health) specializing in pricing and reimbursement strategy.
"Room At The Top? The Case For A Chief Value Officer", In Vivo Pharma Intelligence, vol. 36, no. 10, November 2018
"Bridging the Hidden Hurdle in Cancer Cures", Pharma Exec, 2011
- Life Sciences
Pricing & Market Access/ Value Communication/ Value Based Contracting/ Payer Engagement
- Life Sciences
MBA, Arizona State University, Thunderbird School of Global Management
BS, Biochemistry, University of Pittsburgh
BA, Philosophy, University of Pittsburgh